Baseline clinical parameters, CP-CML risk scores and proportion of BCR-ABL1-positive cells in CD34+ cells subjected to microarray were comparable between responders and non-responders (Table 1, Supplementary Figure 1). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.